{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:14:30Z","timestamp":1770743670975,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40256-024-00686-w","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T02:02:34Z","timestamp":1730512954000},"page":"267-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Drug\u2013Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3181-8680","authenticated-orcid":false,"given":"Dong Ho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-5455","authenticated-orcid":false,"given":"Jang Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-4670","authenticated-orcid":false,"given":"Won Tae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-6178","authenticated-orcid":false,"given":"Kyu-Yeol","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3614-7245","authenticated-orcid":false,"given":"Jae Seok","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5358-8715","authenticated-orcid":false,"given":"Hye Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-1473","authenticated-orcid":false,"given":"JungHa","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1708-9932","authenticated-orcid":false,"given":"Kyu Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2591-4867","authenticated-orcid":false,"given":"Jin-Gyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-0323","authenticated-orcid":false,"given":"Jung","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"686_CR1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s13300-020-00860-8","volume":"11","author":"C-Y Lee","year":"2020","unstructured":"Lee C-Y, Wu T-C, Lin S-J. Long-term cilostazol treatment and predictive factors on outcomes of endovascular intervention in patients with diabetes mellitus and critical limb ischemia. Diabetes Ther. 2020;11:1757\u201373. https:\/\/doi.org\/10.1007\/s13300-020-00860-8.","journal-title":"Diabetes Ther."},{"key":"686_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","volume":"36","author":"RY Kherallah","year":"2022","unstructured":"Kherallah RY, Khawaja M, Olson M, Angiolillo D, Birnbaum Y. Cilostazol: a review of basic mechanisms and clinical uses. Cardiovasc Drugs Ther. 2022;36:777\u201392. https:\/\/doi.org\/10.1007\/s10557-021-07187-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"686_CR3","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3390\/ijms25052593","volume":"25","author":"M Sohn","year":"2024","unstructured":"Sohn M, Lim S. The role of cilostazol, a phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis. Int J Mol Sci. 2024;25:2593. https:\/\/doi.org\/10.3390\/ijms25052593.","journal-title":"Int J Mol Sci"},{"key":"686_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/bs.apha.2016.09.001","volume":"78","author":"T Szasz","year":"2017","unstructured":"Szasz T, Webb RC. Rho-mancing to sensitize calcium signaling for contraction in the vasculature: role of Rho kinase. Adv Pharmacol. 2017;78:303\u201322. https:\/\/doi.org\/10.1016\/bs.apha.2016.09.001.","journal-title":"Adv Pharmacol"},{"key":"686_CR5","doi-asserted-by":"crossref","unstructured":"Lee SW, Park DW, Park SJ. Cilostazol. Antiplatelet Ther Cardiovasc Dis. 2014:117\u201324","DOI":"10.1002\/9781118493984.ch14"},{"key":"686_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.888054","volume":"13","author":"Q Weng","year":"2022","unstructured":"Weng Q, Chen C, Xiong J, Liu Y-N, Pan X, Cui J, et al. Effect of baicalein on the pharmacokinetics of cilostazol and its two metabolites in rat plasma using UPLC\u2013MS\/MS method. Front Pharmacol. 2022;13: 888054. https:\/\/doi.org\/10.3389\/fphar.2022.888054.","journal-title":"Front Pharmacol"},{"key":"686_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.2174\/1389200220666191105115805","volume":"20","author":"I Kaukab","year":"2019","unstructured":"Kaukab I, Hussain Shah SN, Kharaba Z, Murtaza G, Saad AA, Ahmad S. Evaluation of pharmacokinetic interaction of cilostazol with metoclopramide after oral administration in human. Curr Drug Metab. 2019;20:924\u20138. https:\/\/doi.org\/10.2174\/1389200220666191105115805.","journal-title":"Curr Drug Metab"},{"key":"686_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.12793\/tcp.2016.24.4.183","volume":"24","author":"JD Son","year":"2016","unstructured":"Son JD, Cho SM, Choi YW, Kim S-H, Kwon IS, Jin E-H, et al. Pharmacokinetic characteristics of cilostazol 200 mg controlled-release tablet compared with two cilostazol 100 mg immediate-release tablets (Pletal) after single oral dose in healthy Korean male volunteers. Transl Clin Pharmacol. 2016;24:183\u20138. https:\/\/doi.org\/10.12793\/tcp.2016.24.4.183.","journal-title":"Transl Clin Pharmacol."},{"key":"686_CR9","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/DDDT.S86845","volume":"9","author":"YH Kim","year":"2015","unstructured":"Kim YH, Ghim J-L, Jung JA, Cho S-H, Choe S, Choi HY, et al. Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. Drug Des Devel Ther. 2015;9:3571\u20137. https:\/\/doi.org\/10.2147\/DDDT.S86845.","journal-title":"Drug Des Devel Ther."},{"key":"686_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40256-020-00421-1","volume":"20","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Rosuvastatin\/ezetimibe: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2020;20:381\u201392. https:\/\/doi.org\/10.1007\/s40256-020-00421-1.","journal-title":"Am J Cardiovasc Drugs"},{"key":"686_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/TRD-160004","volume":"1","author":"LV Furtado","year":"2016","unstructured":"Furtado LV, Kelley RI, Opitz JM. Disorders of sterol biosynthesis. Transl Sci Rare Dis. 2016;1:145\u201382. https:\/\/doi.org\/10.3233\/TRD-160004.","journal-title":"Transl Sci Rare Dis."},{"key":"686_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/lifemeta\/loac004","volume":"1","author":"J Luo","year":"2022","unstructured":"Luo J, Wang J-K, Song B-L. Lowering low-density lipoprotein cholesterol: from mechanisms to therapies. Life Metab. 2022;1:25\u201338. https:\/\/doi.org\/10.1093\/lifemeta\/loac004.","journal-title":"Life Metab."},{"key":"686_CR13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/medicina58111665","volume":"58","author":"K Zubielien\u0117","year":"2022","unstructured":"Zubielien\u0117 K, Valteryt\u0117 G, Jonaitien\u0117 N, \u017daliaduonyt\u0117 D, Zabiela V. Familial hypercholesterolemia and its current diagnostics and treatment possibilities: a literature analysis. Medicina (Kaunas). 2022;58:1665. https:\/\/doi.org\/10.3390\/medicina58111665.","journal-title":"Medicina (Kaunas)"},{"key":"686_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010254.pub2","author":"SP Adams","year":"2014","unstructured":"Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD010254.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"686_CR15","first-page":"095","volume":"8","author":"W Mak","year":"2016","unstructured":"Mak W, Tan S, Wong J, Chin S, Lim A. Pharmacokinetic comparison and bioequivalence study of two rosuvastatin 20 mg formulations in healthy volunteers. J Bioequiv Availab. 2016;8:095\u20138.","journal-title":"J Bioequiv Availab."},{"key":"686_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5414\/CP202345","volume":"54","author":"Y Harahap","year":"2016","unstructured":"Harahap Y, Prasaja B, Azmi F, Lusthom W, Sinandang T, Felicia V, et al. Bioequivalence study of two rosuvastatin tablet formulations in healthy Indonesian subjects. Int J Clin Pharmacol Ther. 2016;54:212\u20136. https:\/\/doi.org\/10.5414\/CP202345.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"686_CR17","doi-asserted-by":"publisher","first-page":"CMC","DOI":"10.4137\/CMC.S4324","volume":"6","author":"A Luvai","year":"2012","unstructured":"Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol. 2012;6:CMC. https:\/\/doi.org\/10.4137\/CMC.S4324. (S4324:17\u201333).","journal-title":"Clin Med Insights Cardiol."},{"key":"686_CR18","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/s0149-2918(03)80336-3","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2822\u201335. https:\/\/doi.org\/10.1016\/s0149-2918(03)80336-3.","journal-title":"Clin Ther"},{"key":"686_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86:197\u2013203. https:\/\/doi.org\/10.1038\/clpt.2009.79.","journal-title":"Clin Pharmacol Ther"},{"key":"686_CR20","volume-title":"Evaluation of food effects on the oral pharmacokinetics of rosuvastatin","author":"CC McLean","year":"2016","unstructured":"McLean CC. Evaluation of food effects on the oral pharmacokinetics of rosuvastatin. Canada: The University of Western Ontario; 2016."},{"key":"686_CR21","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2174\/1568026619666191122123855","volume":"19","author":"H Zheng","year":"2019","unstructured":"Zheng H, Yang H, Gong D, Mai L, Qiu X, Chen L, et al. Progress in the mechanism and clinical application of cilostazol. Curr Top Med Chem. 2019;19:2919\u201336. https:\/\/doi.org\/10.2174\/1568026619666191122123855.","journal-title":"Curr Top Med Chem"},{"key":"686_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265263","volume":"17","author":"R Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez R, Pe\u00f1a M\u00c1, Torres NS, Torrado G. Design, development, and characterization of amorphous rosuvastatin calcium tablets. PLoS ONE. 2022;17: e0265263. https:\/\/doi.org\/10.1371\/journal.pone.0265263.","journal-title":"PLoS ONE"},{"key":"686_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.pharep.2018.12.005","volume":"71","author":"O Cho","year":"2019","unstructured":"Cho O, Jang Y-J, Park KY, Heo T-H. Beneficial anti-inflammatory effects of combined rosuvastatin and cilostazol in a TNF-driven inflammatory model. Pharmacol Rep. 2019;71:266\u201371. https:\/\/doi.org\/10.1016\/j.pharep.2018.12.005.","journal-title":"Pharmacol Rep"},{"key":"686_CR24","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00210-023-02758-1","volume":"397","author":"A Hamdy","year":"2024","unstructured":"Hamdy A, El-Bassossy HM, Elshazly SM, Shimaa M, Shaimaa S. Rosuvastatin, but not atorvastatin, enhances the antihypertensive effect of cilostazol in an acute model of hypertension. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2024;397:2321\u201334. https:\/\/doi.org\/10.1007\/s00210-023-02758-1.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"10","key":"686_CR25","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/1878-0261.12775","volume":"14","author":"J Longo","year":"2020","unstructured":"Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, et al. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Mol Oncol. 2020;14(10):2533\u201345. https:\/\/doi.org\/10.1002\/1878-0261.12775.","journal-title":"Mol Oncol"},{"key":"686_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/00498250110060950","volume":"31","author":"RJ Weaver","year":"2001","unstructured":"Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica. 2001;31:499\u2013538. https:\/\/doi.org\/10.1080\/00498250110060950.","journal-title":"Xenobiotica"},{"key":"686_CR27","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/jps.21756","volume":"98","author":"AS Kalgutkar","year":"2009","unstructured":"Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, et al. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a \u201cchemical knock-out equivalent\u201d to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci. 2009;98:4914\u201327. https:\/\/doi.org\/10.1002\/jps.21756.","journal-title":"J Pharm Sci"},{"key":"686_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815\u201332. https:\/\/doi.org\/10.1124\/dmd.31.7.815.","journal-title":"Drug Metab Dispos"},{"key":"686_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","volume":"6","author":"MK DeGorter","year":"2013","unstructured":"DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400\u20138. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000099.","journal-title":"Circ Cardiovasc Genet"},{"key":"686_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1248\/bpb.b21-00535","volume":"44","author":"T Yokoyama","year":"2021","unstructured":"Yokoyama T, Yamauchi S, Yamagata K, Kaneshiro Y, Urano Y, Murata K, et al. Impact of cilostazol pharmacokinetics on the development of cardiovascular side effects in patients with cerebral infarction. Biol Pharm Bull. 2021;44:1767\u201374. https:\/\/doi.org\/10.1248\/bpb.b21-00535.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"686_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_106_17","volume":"18","author":"R Hajar","year":"2017","unstructured":"Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart views. 2017;18(3):109\u201314. https:\/\/doi.org\/10.4103\/HEARTVIEWS.HEARTVIEWS_106_17.","journal-title":"Heart views"},{"key":"686_CR32","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.clinthera.2011.10.024","volume":"33","author":"D Lee","year":"2011","unstructured":"Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, et al. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study. Clin Ther. 2011;33:2038\u201353. https:\/\/doi.org\/10.1016\/j.clinthera.2011.10.024.","journal-title":"Clin Ther"},{"key":"686_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40262-020-00978-9","volume":"60","author":"R Kanukula","year":"2021","unstructured":"Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of rosuvastatin: a systematic review of randomised controlled trials in healthy adults. Clin Pharmacokinet. 2021;60:165\u201375. https:\/\/doi.org\/10.1007\/s40262-020-00978-9.","journal-title":"Clin Pharmacokinet"},{"key":"686_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","volume":"75","author":"KC Rogers","year":"2015","unstructured":"Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015;75:377\u201395. https:\/\/doi.org\/10.1007\/s40265-015-0364-3.","journal-title":"Drugs"},{"key":"686_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.02.012","volume":"107","author":"F Cortese","year":"2016","unstructured":"Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, et al. Rosuvastatin: beyond the cholesterol-lowering effect. Pharmacol Res. 2016;107:1\u201318. https:\/\/doi.org\/10.1016\/j.phrs.2016.02.012.","journal-title":"Pharmacol Res"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00686-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00686-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00686-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:28:25Z","timestamp":1739172505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00686-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00686-w","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"24 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Korea United Pharmaceutical Corporation, Seoul, Republic of Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jung WT, Nam K-Y, and Roh JS are employees of Korea United Pharmaceutical Corporation, Seoul, Republic of Korea. Lee HJ, Moon J, and Kim KY are employees of Caleb Multilab Inc., Seoul, Republic of Korea. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Conceptualization: Sunwoo J; data curation: Sunwoo J; formal analysis: Kim DH, Sunwoo J; investigation: Sunwoo J; methodology: Hong JH, Jung J-G; resources: Jung WT, Nam K-Y, Roh JS, Lee HJ, Moon J, Kim KY; supervision: Sunwoo J, Jung J-G; writing\u2014original draft: Kim DH; writing\u2014review and editing: Sunwoo J.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The data that support the findings of this study are available from Korea United Pharmaceutical Corporation, Seoul, Republic of Korea, but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Korea United Pharmaceutical Corporation, Seoul, Republic of Korea.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The trial protocol (KUP-UI022-101) was approved by the Ministry of Food and Drug Safety (MFDS, Republic of Korea) and the Institutional Review Board (IRB) of Chungnam National University Hospital (IRB, CNUH 2016-12-033). All procedures performed in studies involving human participants were in accordance with Good Clinical Practice (ICH-GCP) guidelines, all pertinent Republic of Korea laws, and the ethical standards specified in the applicable version of the declaration of Helsinki. All volunteers gave their written informed consent prior to any study procedures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All volunteers gave their written informed consent prior to any study procedures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}